Canadian Startup Myomar Molecular Brings Urine-Based Muscle Health Testing to Asia.Credit: Myomar Molecular
Across aging societies, sarcopenia—the progressive loss of skeletal muscle mass and strength—poses a mounting healthcare challenge. While longevity medicine increasingly views skeletal muscle as a vital metabolic organ, clinical monitoring has historically remained tethered to hospital-based DEXA scans and physical assessments that capture muscle quantity rather than active cellular turnover.
Spun out of Canada’s Dalhousie University in 2021, healthtech startup Myomar Molecular has engineered a non-invasive alternative: the world’s first urine-based test for muscle health. Operating out of a CLIA-registered facility in the United States and a Health Canada-licensed framework, the company translates metabolic biomarkers into actionable muscular assessments.
The Science of Prevention: Moving Beyond DEXA Scans
“During preclinical validation, we evaluated candidate biomarkers against the gold standards for sarcopenia,” explains Ryan Marshall, Chief Operations Officer of Myomar Molecular. “While no single biomarker alone predicts muscle atrophy, our panel of five biomarkers accurately reflects muscle loss in strong correlation with DEXA scans and physical parameters.” The test examines three metabolic pillars: amino acid profiles supporting protein synthesis, cellular energy metabolites, and markers tracking recovery versus degeneration.
Unlike imaging scans that capture a static snapshot of muscle mass, Myomar’s non-invasive test analyzes muscle metabolism across three core dimensions:1. Amino Acid Analysis: Evaluating circulating building blocks vital for muscle protein synthesis and maintenance. 2. Energy Metabolites: Tracking how efficiently skeletal muscle tissue generates and utilizes cellular energy.3. Recovery & Degeneration Rates: Measuring the dynamic balance between muscle breakdown and repair to identify early signs of muscle wasting before visible frailty occurs.
Currently offered as a Laboratory Developed Test (LDT), the service requires only a standard urine sample. Partner laboratories process the assays, while Myomar’s proprietary software generates an objective muscle score paired with personalized interventions in nutrition, lifestyle, and exercise. Regulated as a low-risk wellness tool, the test does not require FDA clearance, allowing swift clinical integration.
To date, Myomar has partnered with approximately 20 private clinics across Canada specializing in healthy aging, menopause, and medical weight loss. The test has seen rapid uptake among patients using GLP-1 receptor agonists, where rapid weight loss often carries an unintended risk of lean muscle degradation that clinicians must actively monitor and counter.
Why Taiwan and Asia
Participating in the Canadian Technology Accelerator (CTA) program, Marshall is visiting Taiwan to anchor the company’s Asia-Pacific expansion. Rather than establishing overseas brick-and-mortar facilities, Myomar aims to license its assay technology to accredited Taiwanese diagnostic laboratories. Under this model, local labs handle sample processing, while Myomar provides the computational scoring and clinical guidance.
Simultaneously, the company is engaging Taiwanese private longevity and executive health clinics to build test volume, while seeking local hardware partners. Beyond its current lab-based test, Myomar is developing an over-the-counter lateral flow strip—resembling a rapid antigen test—that delivers semi-quantitative readings via colorimetric bands. While Myomar has validated the underlying lateral flow chemistry, it is actively seeking Taiwanese electronics and optical manufacturers to co-develop the digital readers and point-of-care analyzers required for consumer rollout and future in vitro diagnostic (IVD) hospital tools.
Investment is another key CTA objective. Having secured CAD 4 million to date—over half from non-dilutive government funding, alongside backing from Japanese multinational Suntory—Myomar is raising a US 3 million seed bridge extension to finance North American commercial expansion and prepare for laboratory out-licensing. Marshall notes that while several Asian investors have expressed interest, the priority is securing a lead investor to finalize the priced round. Beyond Taiwan, Myomar is advancing discussions in Japan, South Korea, and Singapore, with long-term sights on Hong Kong and mainland China.
Addressing the optimal window for testing, Marshall advocates early baseline screening. “Sarcopenia onset typically begins in your 30s and progresses quietly unless countered,” he explains. “Hormonal shifts like perimenopause and lifestyle changes accelerate this decline. We recommend establishing a baseline in your 30s.
The Future of Muscular Longevity
As healthcare shifts from reactive sick-care to proactive, biomarker-guided preventative medicine, Myomar Molecular is positioning itself to become the global gold standard in muscle health assessment.
“Our long-term vision is a healthcare system where primary care physicians and longevity specialists can assess muscle health instantly, prescribe precise lifestyle and nutritional regimens, and track efficacy with molecular precision,” concludes Marshall. “By catching muscle degradation decades before frailty sets in, we can fundamentally alter the trajectory of aging.”